ReproCell (4978.T) Stock Price

ReproCell Price

JPX·CLOSED
129.00JPY+2.00 (+1.56 %)
Market closed

Over the last 17 years ReproCell grew revenue by 25.1% annually, reaching 2.98 B JPY. For ReproCell, the net margin of 3.5% is up versus -63.2% a few years ago. The consensus 12-month price target for ReproCell is 275.40 JPY, about 113.5% above where the stock trades today. Of 7 analysts, 0 rate the stock a buy — an overall Sell consensus. The stock trades about 8% above its 52-week low.

ReproCell stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of ReproCell over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how ReproCell stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing ReproCell's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

ReproCell Stock Price History
DateReproCell Price
7/10/2026129.00 JPY
7/9/2026127.00 JPY
7/8/2026124.00 JPY
7/7/2026127.00 JPY
7/6/2026126.00 JPY
7/3/2026128.00 JPY
7/2/2026124.00 JPY
7/1/2026126.00 JPY
6/30/2026125.00 JPY
6/29/2026128.00 JPY
6/26/2026128.00 JPY
6/25/2026132.00 JPY
6/24/2026120.00 JPY
6/23/2026122.00 JPY
6/22/2026123.00 JPY
6/19/2026126.00 JPY
6/18/2026126.00 JPY
6/17/2026130.00 JPY
6/16/2026126.00 JPY
6/15/2026128.00 JPY
6/12/2026127.00 JPY
6/11/2026126.00 JPY
6/10/2026126.00 JPY
6/9/2026129.00 JPY
6/8/2026125.00 JPY
6/5/2026129.00 JPY
6/4/2026127.00 JPY
6/3/2026127.00 JPY
6/2/2026123.00 JPY
6/1/2026127.00 JPY
5/29/2026130.00 JPY
5/28/2026129.00 JPY
5/27/2026141.00 JPY
5/26/2026141.00 JPY
5/25/2026143.00 JPY
5/22/2026145.00 JPY
5/21/2026143.00 JPY
5/20/2026137.00 JPY
5/19/2026152.00 JPY
5/18/2026153.00 JPY
5/15/2026169.00 JPY
5/14/2026166.00 JPY
5/13/2026169.00 JPY
5/12/2026167.00 JPY
5/11/2026171.00 JPY
5/8/2026174.00 JPY
5/7/2026176.00 JPY
5/1/2026173.00 JPY
4/30/2026172.00 JPY
4/28/2026171.00 JPY
4/27/2026172.00 JPY
4/24/2026173.00 JPY
4/23/2026175.00 JPY
4/22/2026177.00 JPY
4/21/2026177.00 JPY
4/20/2026180.00 JPY
4/17/2026180.00 JPY
4/16/2026183.00 JPY
4/15/2026180.00 JPY
4/14/2026181.00 JPY
4/13/2026178.00 JPY
4/10/2026179.00 JPY
4/9/2026182.00 JPY
4/8/2026182.00 JPY
4/7/2026172.00 JPY
4/6/2026172.00 JPY
4/3/2026168.00 JPY
3/27/2026183.00 JPY
3/26/2026175.00 JPY
3/25/2026176.00 JPY
3/24/2026174.00 JPY
3/23/2026163.00 JPY
3/19/2026169.00 JPY
3/18/2026175.00 JPY
3/17/2026170.00 JPY
3/16/2026171.00 JPY
3/13/2026166.00 JPY
3/12/2026176.00 JPY
3/11/2026186.00 JPY
3/9/2026178.00 JPY
3/6/2026192.00 JPY
3/5/2026177.00 JPY
2/26/2026180.00 JPY
2/25/2026183.00 JPY
2/24/2026170.00 JPY
2/20/2026171.00 JPY
2/19/2026178.00 JPY
2/18/2026167.00 JPY
2/17/2026161.00 JPY
2/16/2026163.00 JPY
2/13/2026148.00 JPY
2/12/2026161.00 JPY
2/10/2026164.00 JPY
2/9/2026160.00 JPY
2/6/2026159.00 JPY
2/5/2026163.00 JPY
2/4/2026159.00 JPY
2/3/2026163.00 JPY
2/2/2026160.00 JPY
1/30/2026159.00 JPY
1/29/2026158.00 JPY
1/28/2026163.00 JPY
1/27/2026162.00 JPY
1/26/2026164.00 JPY
1/23/2026170.00 JPY
1/22/2026168.00 JPY
1/21/2026165.00 JPY
1/20/2026171.00 JPY
1/19/2026178.00 JPY
1/16/2026171.00 JPY
1/15/2026179.00 JPY
1/14/2026156.00 JPY
1/13/2026159.00 JPY
1/9/2026149.00 JPY
1/8/2026152.00 JPY
1/7/2026149.00 JPY
1/6/2026151.00 JPY
1/5/2026146.00 JPY
12/30/2025140.00 JPY
12/29/2025144.00 JPY
12/26/2025143.00 JPY
12/25/2025144.00 JPY
12/24/2025138.00 JPY
12/23/2025140.00 JPY
12/22/2025140.00 JPY
12/19/2025147.00 JPY
12/18/2025146.00 JPY
12/17/2025145.00 JPY
12/16/2025146.00 JPY
12/15/2025151.00 JPY
12/12/2025149.00 JPY
12/11/2025149.00 JPY
12/10/2025152.00 JPY
12/9/2025152.00 JPY
12/8/2025154.00 JPY
12/5/2025157.00 JPY
12/4/2025162.00 JPY
12/3/2025153.00 JPY
12/2/2025155.00 JPY
12/1/2025158.00 JPY
11/28/2025162.00 JPY
11/27/2025161.00 JPY
11/26/2025160.00 JPY
11/25/2025155.00 JPY
11/21/2025161.00 JPY
11/20/2025160.00 JPY
11/19/2025158.00 JPY
11/18/2025160.00 JPY
11/17/2025157.00 JPY
11/14/2025161.00 JPY
11/13/2025168.00 JPY
11/12/2025172.00 JPY
11/11/2025169.00 JPY
11/10/2025170.00 JPY
11/7/2025168.00 JPY
11/6/2025173.00 JPY
11/5/2025170.00 JPY
11/4/2025173.00 JPY
10/31/2025177.00 JPY
10/30/2025177.00 JPY
10/29/2025172.00 JPY
10/28/2025178.00 JPY
10/27/2025181.00 JPY
10/24/2025180.00 JPY
10/23/2025184.00 JPY
10/22/2025187.00 JPY
10/21/2025183.00 JPY
10/20/2025180.00 JPY
10/17/2025175.00 JPY
10/16/2025183.00 JPY
10/15/2025186.00 JPY
10/14/2025175.00 JPY
10/10/2025186.00 JPY
10/9/2025184.00 JPY
10/8/2025183.00 JPY
10/7/2025188.00 JPY
10/6/2025190.00 JPY
10/3/2025187.00 JPY
10/2/2025186.00 JPY
10/1/2025186.00 JPY
9/30/2025194.00 JPY
9/29/2025194.00 JPY
9/26/2025201.00 JPY
9/25/2025200.00 JPY
9/24/2025197.00 JPY
9/22/2025204.00 JPY
9/19/2025206.00 JPY
9/18/2025200.00 JPY
9/17/2025209.00 JPY
9/16/2025210.00 JPY
9/12/2025192.00 JPY
9/11/2025188.00 JPY
9/10/2025191.00 JPY
9/9/2025194.00 JPY
9/8/2025195.00 JPY
9/5/2025196.00 JPY
9/4/2025188.00 JPY
9/3/2025184.00 JPY
9/2/2025187.00 JPY
9/1/2025185.00 JPY
8/29/2025181.00 JPY
8/28/2025178.00 JPY
8/27/2025179.00 JPY
8/26/2025184.00 JPY
8/25/2025189.00 JPY
8/22/2025184.00 JPY
8/21/2025181.00 JPY
8/20/2025182.00 JPY
8/19/2025188.00 JPY
8/18/2025187.00 JPY
8/15/2025186.00 JPY
8/14/2025189.00 JPY
8/13/2025211.00 JPY
8/12/2025216.00 JPY
8/8/2025217.00 JPY
8/7/2025218.00 JPY
8/6/2025218.00 JPY
8/5/2025215.00 JPY
8/4/2025209.00 JPY
8/1/2025212.00 JPY
7/31/2025207.00 JPY
7/30/2025214.00 JPY
7/29/2025215.00 JPY
7/28/2025225.00 JPY
7/25/2025216.00 JPY
7/24/2025211.00 JPY
7/23/2025212.00 JPY
7/22/2025197.00 JPY
7/18/2025198.00 JPY
7/17/2025209.00 JPY
7/16/2025214.00 JPY
7/15/2025212.00 JPY
7/14/2025214.00 JPY
Access this data via the Eulerpool API
Get Free API Key

ReproCell Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
1.09 B JPY
-781.12 M JPY
-601.42 M JPY
Jan 1, 2020
1.20 B JPY
-908.94 M JPY
-1.02 B JPY
Jan 1, 2021
1.29 B JPY
-1.05 B JPY
-812.57 M JPY
Jan 1, 2022
2.23 B JPY
-647.13 M JPY
-575.09 M JPY
Jan 1, 2023
2.95 B JPY
-356.22 M JPY
-305.31 M JPY
Jan 1, 2024
2.43 B JPY
-409.29 M JPY
-31.42 M JPY
Jan 1, 2025
2.98 B JPY
-130.41 M JPY
103.25 M JPY
Jan 1, 2026 (e)
3.38 B JPY
0.00 JPY
-21.57 M JPY

ReproCell Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 12, 2026, 4:18 AM
 
REVENUEB JPY
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB JPY
NET INCOMEB JPY
NET INCOME GROWTH%
SHARESM
2011201220132014201520162017201820192020202120222023202420252026e
0.280.320.420.460.571.071.260.931.091.201.292.232.952.432.983.38
25.7913.6732.919.7622.9988.0117.92-26.3317.4910.207.2673.7232.18-17.8522.7513.63
48.5650.3253.1055.5348.6849.9145.8241.1445.5939.5337.4835.9438.6446.1755.3755.37
0.140.160.220.260.280.530.580.380.500.470.480.801.141.121.651.87
-0.03-0.020.01-0.13-0.45-1.96-0.91-2.17-0.60-1.02-0.81-0.58-0.31-0.030.10-0.02
-32.00-35.29-122.73-2,760.00239.10334.81-53.54138.42-72.3369.05-20.08-29.19-46.96-89.84-432.26-120.39
38.3038.3038.3043.5050.1654.2458.1463.3668.4071.2671.4375.9584.2385.6292.8592.85
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales ReproCell generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue ReproCell retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare ReproCell's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares ReproCell has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against ReproCell's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

ReproCell stock margins

The ReproCell margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ReproCell. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ReproCell.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
45.61 %
-71.76 %
-55.25 %
Jan 1, 2020
39.56 %
-75.75 %
-84.72 %
Jan 1, 2021
37.53 %
-81.48 %
-63.17 %
Jan 1, 2022
35.95 %
-28.96 %
-25.74 %
Jan 1, 2023
38.64 %
-12.06 %
-10.34 %
Jan 1, 2024
46.19 %
-16.87 %
-1.29 %
Jan 1, 2025
55.36 %
-4.38 %
3.47 %
Jan 1, 2026 (e)
55.36 %
0.00 %
-0.64 %

ReproCell Stock Revenue, EBIT, Earnings per Share

The ReproCell earnings per share therefore indicates how much revenue ReproCell has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2019
15.91 JPY
-11.42 JPY
-8.79 JPY
Jan 1, 2020
16.84 JPY
-12.76 JPY
-14.27 JPY
Jan 1, 2021
18.01 JPY
-14.67 JPY
-11.38 JPY
Jan 1, 2022
29.42 JPY
-8.52 JPY
-7.57 JPY
Jan 1, 2023
35.06 JPY
-4.23 JPY
-3.62 JPY
Jan 1, 2024
28.34 JPY
-4.78 JPY
-0.37 JPY
Jan 1, 2025
32.08 JPY
-1.40 JPY
1.11 JPY
Jan 1, 2026 (e)
36.44 JPY
0.00 JPY
-0.23 JPY

ReproCell business model & stock analysis

ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future.

ReproCell SWOT Analysis

Strengths

ReproCell Inc has a strong reputation in the industry for its high-quality products and services, which has enabled the company to build a loyal customer base.

The company has a robust research and development team, enabling it to continuously innovate and stay ahead of competitors.

ReproCell Inc has established strong partnerships with key industry players, allowing it to access new markets and expand its customer base.

Weaknesses

One of the weaknesses of ReproCell Inc is its limited geographical presence, as it primarily operates in a few regions. This puts the company at a disadvantage compared to competitors with a broader global reach.

The company heavily relies on a few key customers for a significant portion of its revenue, making it vulnerable to any changes in their demands or business situations.

ReproCell Inc has faced challenges in scaling its production capacity to meet increasing demand, which has led to occasional supply chain disruptions.

Opportunities

There is a growing global demand for regenerative medicine and stem cell research, presenting significant opportunities for ReproCell Inc to expand its market share.

The company can explore untapped geographical markets by establishing partnerships or opening new branches in regions where it currently has a limited presence.

ReproCell Inc can diversify its product and service offering to cater to a wider range of customer needs, such as introducing new technologies or expanding into related fields.

Threats

The competitive landscape in the regenerative medicine industry is intense, with several established players and new entrants vying for market share. This poses a threat to ReproCell Inc's market position.

Changes in regulations and policies related to stem cell research and regenerative medicine can significantly impact ReproCell Inc's operations and restrict its ability to expand or operate in certain markets.

The ongoing COVID-19 pandemic has disrupted supply chains and impacted the overall demand for medical products and services, including those offered by ReproCell Inc.

ReproCell Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

ReproCell historical P/E ratio, EBIT multiple, and P/S ratio

ReproCell annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

ReproCell shares outstanding

The number of shares of ReproCell was 92.85 M in 2025. This indicates how many shares ReproCell is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
68.40 M Stocks
Jan 1, 2020
71.26 M Stocks
Jan 1, 2021
71.43 M Stocks
Jan 1, 2022
75.95 M Stocks
Jan 1, 2023
84.23 M Stocks
Jan 1, 2024
85.62 M Stocks
Jan 1, 2025
92.85 M Stocks
Jan 1, 2026 (e)
92.85 M Stocks

ReproCell stock splits

In ReproCell's history, there have been no stock splits.

Current ReproCell forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy0.00 % (0)
Hold42.86 % (3)
Sell57.14 % (4)
12M Price Target
275.40
Last Price
129.00
Currency
JPY
12M Return Potential
113.49 %
LTM Return
0 %

ReproCell Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
11/9/2022-1.25JPY622.19 MJPY2023 Q2
8/10/2022-1.47JPY375.55 MJPY2023 Q1
5/13/20220.22JPY580.58 MJPY2022 Q4
2/10/2022-9.31JPY456.75 MJPY2022 Q3
11/12/2021-3.46JPY235.48 MJPY2022 Q2
8/13/2021-2.94JPY170.52 MJPY2022 Q1
5/12/2021-JPY346.11 MJPY2021 Q4
2/12/2021-3.11JPY334.95 MJPY2021 Q3
11/12/2020-3.85JPY458.78 MJPY2021 Q2
9/29/2020-3.54JPY294.35 MJPY2021 Q1

ReproCell shareholder structure

% Name
1.19216%
Yokoyama (Chikafumi)
Yokoyama (Chikafumi)
1.07698%
Ueda Yagi Tanshi Co., Ltd.
Ueda Yagi Tanshi Co., Ltd.
0.89238%
Isohata (Teruo)
Isohata (Teruo)
0.75668%
State Street Global Advisors (US)
State Street Global Advisors (US)
0.75388%
Nakano (Akira)
Nakano (Akira)
0.70488%
JPMorgan Securities Japan Co., Ltd.
JPMorgan Securities Japan Co., Ltd.

ReproCell Executives and Management Board

CY

Mr. Chikafumi Yokoyama

(45)

President, Chairman of Subsidiaries, Representative Director · since 2011

SM

Mr. Satoshi Munemura

(41)

Chief Financial Officer, General Manager of Business Administration Unit

DU

Mr. Daisuke Usui

(48)

Chief Operating Officer, Director · since 2020

SA

Mr. Shigetomo Akano

(41)

Director · since 2020

YY

Mr. Yoshiyuki Yamakawa

(60)

Independent Director

ReproCell Supply Chain

ReproCell Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
6 companies
#Name1M3M6M1Y2YTrend
1
Hoth Therapeutics
Supplier
0.81
0.72
0.62
0.94
0.89
#Name1M3M6M1Y2YTrend
1
Thermo Fisher Scientific
0.09
0.58
0.54
-0.50
-0.87
2
Addtech B
0.32
0.70
0.58
-0.31
-0.82
3
AGC
Supplier
0.43
0.15
0.31
-0.20
-0.76
4
FUJIFILM Holdings
0.72
0.63
0.53
0.29
-0.73
5
Seoulin Bioscience
0.06
0.40
0.45
0.73
-0.29

Frequently asked questions about ReproCell

ReproCell Inc is a leading company in the field of stem cell research and drug discovery. Their business model revolves around providing innovative solutions for regenerative medicine through the development of human-derived stem cell products and services. ReproCell Inc focuses on utilizing induced pluripotent stem cells (iPSCs) to generate disease-specific models for drug screening and toxicity testing. By offering high-quality iPSC-derived products, such as neural cells, hepatocytes, and cardiomyocytes, ReproCell aims to meet the diverse needs of the pharmaceutical industry, academic research, and clinical applications. With their expertise in stem cell technology, ReproCell Inc is dedicated to advancing the development of personalized medicine and improving patient outcomes.

All fundamentals and in-depth analysis of ReproCell

Our stock analysis for ReproCell stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ReproCell. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

ReproCell Stock
ReproCell Revenue→
ReproCell Stock
ReproCell Net Income→
ReproCell Stock
ReproCell P/E→
ReproCell Stock
ReproCell P/S→
ReproCell Stock
ReproCell EBIT→
ReproCell Stock
ReproCell Dividend→
ReproCell Stock
ReproCell Directors Dealings→
ReproCell Stock
ReproCell Stocks→
ReproCell Stock
ReproCell Market capitalization→
ReproCell Stock
ReproCell Debt→
ReproCell Stock
ReproCell Liabilities→
ReproCell Stock
ReproCell Equity→
ReproCell Stock
ReproCell AAQS→
ReproCell Stock
ReproCell Employees→
ReproCell Stock
ReproCell ROE→
ReproCell Stock
ReproCell ROA→
ReproCell Stock
ReproCell ROCE→
ReproCell Stock
ReproCell News→
ReproCell Stock
ReproCell Analyst Price Targets→

Health Stocks

Republic HealthcareReplimune GroupResapp HealthRepligenResmedRenovoRxResonance HealthRenovaCareRespiratorius AB (publ)Rennova HealthResponse GeneticsRenhe Pharmacy CoAll Stocks A–Z →